Abstract: A method for network access, a terminal, and a storage medium are provided. The method includes that: the terminal acquires a first frequency band corresponding to a first cell where the terminal camps; determines whether the first frequency band belongs to a second frequency band predetermined by the terminal; and performs handover to a second cell which is different from the first cell in response to determining that the first frequency band does not belong to the second frequency band.

Abstract: A compound represented by the general Formula I, a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof for preventing and/or treating a pulmonary disease or symptom associated with SARS-CoV-2 or an asymptomatic or symptomatic SARS-CoV-2 infection, and an application of the compound represented by the general Formula I, the geometric isomer thereof, or the pharmaceutically acceptable salt thereof, and/or the solvate thereof, and/or the hydrate thereof in preparation of a product for preventing and/or treating a pulmonary disease or symptom associated with SARS-CoV-2 or asymptomatic or symptomatic SARS-CoV-2 infection,

Abstract: The present application provides a recombinant fusion protein containing an anti-CD38 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD38 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD38 using the recombinant fusion protein.

Abstract: Disclosed is an antibody that specifically binds CD70, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD70 signaling using the antibody or antigen binding portion thereof are also provided.

Abstract: Disclosed is an antibody that specifically binds CD24, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD24 signaling using the antibody or antigen binding portion thereof are also provided.

Abstract: The present application provides a recombinant fusion protein containing an anti-CD24 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD24 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope, wherein the recombinant fusion protein can bind to CD47, CD24 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD24 using the recombinant fusion protein.

Abstract: Disclosed is an antibody that specifically binds CD70, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD70 signaling using the antibody or antigen binding portion thereof are also provided.

Abstract: Techniques are described with regard to managing transaction size during a database replication process. An associated computer-implemented method includes identifying each of at least one transaction associated with at least one source database stored in a replication capture memory, identifying at least one potential excessive memory transaction by applying, via at least one machine learning pattern detection model, pattern detection to each of the at least one transaction stored in the replication capture memory, and constructing at least one compact data unit associated with each of the at least one potential excessive memory transaction. The computer-implemented method further includes facilitating compact data unit transmission to a replication apply server system in order to replicate the at least one compact data unit associated with each of the at least one potential excessive memory transaction to at least one target database via a replication apply server application.

Abstract: The present application provides a recombinant fusion protein containing an anti-PD-L1 antibody or an antibody fragment thereof, with each paratope of the anti-PD-L1 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain variable region or a light chain variable region constituting the paratope, wherein the recombinant fusion protein can bind to CD47, PD-L1 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over-expression of CD47 and/or PD-L1 using the recombinant fusion protein.

Abstract: Nitazoxanide represented by formula I and an active form thereof, tizoxanide compound, represented by formula II, a geometric isomer thereof and pharmaceutically acceptable salt thereof and/or solvate thereof and/or hydrate thereof, and a pharmaceutical composition containing this compound, used for preventing and/or treating coronavirus (such as SARS-CoV-2) infection.

Abstract: A use of ritonavir, or a geometric isomer, pharmaceutically acceptable salt, solvate, and/or hydrate thereof, and a pharmaceutical composition containing the above compound in treating a SARS-CoV-2 infections.

Abstract: A drug delivery system is described comprising a detachable support and a plurality of drug-loaded transdermal microneedles, for delivering drugs into gingival tissue for the treatment of periodontal disease.

Abstract: A display controller, comprising a 3D_LUT random access memory, which stores at least a 3D Lookup table; and a display control processing unit, comprising: a computing unit, a register, a color signal booster, and a color signal attenuator; wherein after input color signals are received by the color signal booster, and the color signal booster amplifies color signals by a first predetermined factor, wherein the computing unit calculates the address of the 3D Lookup table, and loads the 3D Lookup table from the 3D_LUT random access memory according to the register, wherein the color signal attenuator attenuates color signals by a second predetermined factor. The present disclosure significantly increases the precision of color conversion from one RGB color space to another RGB color space, and does not increase the RAM cost, since the cost of multiplying or dividing by power of 2, for example, is limited.

Abstract: A nitrogen-containing ring derivative regulator, a preparation method therefor and use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof as a G protein-coupled receptor regulator in the treatment or prevention of central nervous system diseases and/or mental diseases.

Abstract: The present invention relates to a vaginal drug delivery device configured to safely and effectively deliver a therapeutic formulation in the vagina at or near a desired target area for a specified time period.

Abstract: A rotary printing integrated ink box special for seal printing comprises an ink box body (1) with a cylindrical or elliptic cylindrical outer contour, a spray head (6) with a circuit board (5) is arranged outside the ink box body (1), the spray head (6) corresponds to an ink outlet (3), and contacts (7) connected with control lines of the spray head (6) are integrated on the circuit board (5); and a rotary fixed surface of the ink box body (1) is parallel to a rotary injection surface of the spray head (6).

Abstract: 2-Benzylidene hydrazinoadenosine compounds having A2A adenosine receptor agonistic activity, represented by a general Formula (I) and pharmaceutical compositions containing the same. The compounds and compositions can act as A2A adenosine receptor agonist to serve as medicaments.

Abstract: The present disclosure provides 6-hydrazinoadenosine represented by the general Formula (I) and its derivatives with A2A adenosine receptor agonist activity, and pharmaceutical compositions containing them. The compound and composition can be used as A2A adenosine receptor agonists and used as medicament.

Abstract: A multi-line laser radar includes a first radar component, where the first radar component includes n lasers, an optical collimating unit, a scanning rotating mirror, and a detector, where n is greater than 1. Each laser is configured to emit one laser beam to the optical collimating unit. The optical collimating unit is configured to collimate n laser beams, where the collimated n laser beams are incident on a target reflector of the scanning rotating mirror. The scanning rotating mirror includes m reflectors rotating around a rotation axis, where a rotation plane of the rotation axis is perpendicular to an arrangement direction of the collimated n laser beams, and m is greater than 1. The target reflector reflects the received collimated n laser beams to a detection area of the first radar component. The detector receives echo signals of the reflected n laser beams in the detection area.

Abstract: The present application provides a small-molecule compound, represented by general Formula (I), having A2A adenosine receptor antagonistic activity and a pharmaceutical composition containing same. The compound and composition can be used as A2A adenosine receptor antagonistic agents.